Login to Your Account

FDA Says Corixa’s Bexxar BLA Not Enough To Gain Approval

By Kim Coghill

Thursday, March 14, 2002
Corixa Corp.’s stock took a dive Wednesday after the FDA said in a “complete review letter” that the company failed to provide sufficient evidence of safety and clinical benefit in its biologics license application for the non-Hodgkin’s lymphoma drug Bexxar. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription